E Fund Management Co., Ltd. Veracyte, Inc. Transaction History

E Fund Management Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$21.0 - $29.1 $126,336 - $175,065	6,016 Added 70.24%	14,581 $323,000
Q4 2023 Feb 06, 2024	SELL	$19.72 - $28.68 $46,302 - $67,340	-2,348 Reduced 21.52%	8,565 $235,000
Q3 2023 Nov 13, 2023	SELL	$22.33 - $29.92 $48,500 - $64,986	-2,172 Reduced 16.6%	10,913 $244,000
Q2 2023 Aug 11, 2023	SELL	$20.96 - $26.99 $71,725 - $92,359	-3,422 Reduced 20.73%	13,085 $333,000
Q1 2023 May 11, 2023	BUY	$20.58 - $27.89 $35,809 - $48,528	1,740 Added 11.78%	16,507 $368,000
Q4 2022 Feb 14, 2023	SELL	$15.31 - $29.94 $137,713 - $269,310	-8,995 Reduced 37.85%	14,767 $350,000
Q3 2022 Nov 14, 2022	BUY	$16.58 - $27.9 $15,684 - $26,393	946 Added 4.15%	23,762 $394,000
Q2 2022 Aug 15, 2022	BUY	$15.45 - $29.52 $178,293 - $340,660	11,540 Added 102.34%	22,816 $454,000
Q1 2022 May 12, 2022	BUY	$21.94 - $42.51 $189,429 - $367,031	8,634 Added 326.8%	11,276 $311,000
Q1 2021 May 12, 2021	BUY	$44.47 - $81.38 $117,489 - $215,005	2,642 New	2,642 $142,000

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.